Functional Studies of High Density Lipoprotein in the Metabolic Syndrome
试验速览
- 阶段
- 不适用
- 入组人数
- 30
- 试验地点
- 1
研究概览
简要总结
The aim of the study is to examine the kinetic, anti-oxidant, anti-inflammatory and cellular cholesterol efflux properties of high-density lipoprotein (HDL) in subjects with the metabolic syndrome (MetS) and lean individuals.
详细描述
Background and Purpose of This Study:
The metabolic syndrome (MetS) is characterized by impaired glucose and insulin metabolism (insulin resistance), abnormal body fat distribution called central obesity (a pot belly) and high blood pressure. People with the metabolic syndrome have markedly increased risk of heart disease which is mainly attributed to the abnormal fat metabolism and its associated metabolic disorders. Therefore, understanding of the body fat disorder is important to reduce the incidence and severity of heart disease.
Fats in the blood originate from dietary sources and from production by the liver. They are then delivered into peripheral body cell for utilization or storage. A particular protein, called high-density lipoprotein (HDL) apolipoprotein (apo) A-I, is an important fat carrier responsible for transporting excess fat from cells, via the bloodstream, back to the liver. Low HDL-apoA-I concentration is related to increased risk of heart disease. Subjects with MetS have reduced level of apoA-I and we wish to test the hypothesis that it is responsible for the impaired movement of fat from the periphery to the liver. Recent evidence suggests that the functionality of HDL, including anti-oxidant, anti-inflammatory and cholesterol efflux properties, is also important in preventing the development of heart disease. However, these function tests have not yet been investigated extensively in MetS.
Consequently, we wish to examine the transport and anti-atherogenic properties of HDL in subjects with MetS and compare these with normal lean subjects. Such findings would be of significant clinical importance in the understanding of the diverse role of HDL-apoA-I in reducing or preventing the progression of heart disease.
Participation:
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 20 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •MetS :the presence of at least three of the following:
- •waist circumference > 102 cm, triglycerides > 1.7 mmol/L, HDL cholesterol < 1.05 mmol/L
- •blood pressure ≥ 130/ ≥ 85 mmHg
- •fasting glucose > 6.1 mmol/L
- •Lean control:
- •BMI < 25 kg/m2
- •waist circumference < 102 cm
- •triglycerides < 1.0 mmol/L
- •HDL-cholesterol > 1.3 mmol/L
排除标准
- •subjects with plasma LDL-cholesterol > 5 mmo/L
- •diabetes mellitus (defined by oral glucose tolerance test)
- •genetic hyperlipidaemia (e.g. FH)
- •consumption of > 30 g alcohol/day
- •apolipoprotein E2/E2 genotype
- •macroproteinuria
- •creatinaemia ( > 120 umol/L)
- •hypothyroidism
- •hepatic dysfunction (AST or ALT > 2x ULN)
- •major systemic illness and use of steroids or other agents that may influence lipid metabolism
- •cardiovascular event within the past 6 months
- •subjects on hypocaloric diets
- •anaemia; any significant illness that in the opinion of reviewing physician would bear on the study (e.g. heart murmur or psychiatric conditions)